Globus Medical, Inc. (GMED) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $79.93, but acceptable to hold if already in. Reasons: Leverage penalty (D/E 2.5): -1.5; Negative news sentiment (-0.67).
Globus Medical is a musculoskeletal solutions company designing and selling spine, trauma, and enabling technology products — including surgical robots (ExcelsiusGPS) — to hospitals and surgical facilities globally. It earns revenue through direct and distributor-based device... Read more
Hold if already holding. Not a fresh buy at $79.93, but acceptable to hold if already in. Reasons: Leverage penalty (D/E 2.5): -1.5; Negative news sentiment (-0.67). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 7.1/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent Developments — Globus Medical, Inc.
Latest news
- Globus Medical (GMED) Stock: Technical Signals Overview | Q4 2025: Better Than Expected - Acquisition - Newser — Newser positive
- Globus Medical (GMED) Stock: Technical Signals Overview | Q4 2025: Better Than Expected - Crowd Breakout Signals - Newse — Newser positive
- Down 13.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Globus Medical (GMED) - MSN — MSN negative
- Globus Medical (GMED) Q1 earnings preview: What you should know beyond the headline estimates - MSN — MSN neutral
- How Upgraded Estimates and Zacks Rank #1 Status Will Impact Globus Medical (GMED) Investors - Yahoo Finance — Yahoo Finance positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $79.93, but acceptable to hold if already in. Reasons: Leverage penalty (D/E 2.5): -1.5; Negative news sentiment (-0.67). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $97.00 (+21.4%), stop $74.33 (−7.5%), A.R:R 2.5:1. Score 7.1/10, moderate confidence.
Take-profit target: $97.00 (+21.4% upside). Target $97.00 (+21.4%), stop $74.33 (−7.5%), A.R:R 2.5:1. Stop-loss: $74.33.
Leverage penalty (D/E 2.5): -1.5; Negative news sentiment (-0.67).
Globus Medical, Inc. trades at a P/E of 18.4 (forward 15.4). TrendMatrix value score: 7.8/10. Verdict: Hold.
22 analysts cover GMED with a consensus score of 3.9/5. Average price target: $112.
What does Globus Medical, Inc. do?Globus Medical is a musculoskeletal solutions company designing and selling spine, trauma, and enabling technology...
Globus Medical is a musculoskeletal solutions company designing and selling spine, trauma, and enabling technology products — including surgical robots (ExcelsiusGPS) — to hospitals and surgical facilities globally. It earns revenue through direct and distributor-based device sales, with approximately 80% from the U.S. market following its 2023 NuVasive merger.